Humoral response to SARS-CoV-2 after vaccination and booster effect in patients undergoing dialysis.

Autor:	Hernández-Porto M; University Hospital of the Canary Islands, Microbiology Service, Ofra s/n 38320 La Laguna, Spain; University of La Laguna, Faculty of Medicine, Ofra s/n 38320 La Laguna, Spain. Electronic address: portomiri@hotmail.com., García S; University Hospital of the Canary Islands, Nephrology Service, Ofra s/n 38320 La Laguna, Spain., Delgado T; University Hospital of the Canary Islands, Microbiology Service, Ofra s/n 38320 La Laguna, Spain., Rodriguez Y; University Hospital of the Canary Islands, Nephrology Service, Ofra s/n 38320 La Laguna, Spain., Aguirre-Jaime A; Institute for Healthcare Research of the Nursing School of Santa Cruz de Tenerife, Santa Cruz de Tenerife, C/ San Martín, n ° 62, C. P: 38001, Spain., Campos S; University Hospital of the Canary Islands, Microbiology Service, Ofra s/n 38320 La Laguna, Spain., Hernández C; University of La Laguna, Faculty of Medicine, Ofra s/n 38320 La Laguna, Spain., Lorenzo C; University Hospital of the Canary Islands, Microbiology Service, Ofra s/n 38320 La Laguna, Spain., Lecuona M; University Hospital of the Canary Islands, Microbiology Service, Ofra s/n 38320 La Laguna, Spain.
Jazyk:	angličtina
Zdroj:	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2022 Sep; Vol. 122, pp. 327-331. Date of Electronic Publication: 2022 Jun 04.
DOI:	10.1016/j.ijid.2022.05.065
Abstrakt:	Objective: The aim of this study was to determine and evaluate the postvaccination variation in immunoglobulin G (IgG) receptor-binding domain (RBD) produced in non-SARS-CoV-2-infected patients with nephropathy and renal replacement therapy. Methods: This is a follow-up study of the humoral response to the BNT162b2 messenger ribonucleic acid COVID-19 vaccine in patients with nephropathy, comparing it with itself at different times and with the healthy population. Results: In patients with nephropathy, a very striking decrease in IgG RBD was observed compared with the healthy population (P<0.001) at three months after the second dose. In patients with nephropathy, the response rate ≥590 binding antibody units/ml (4154 AU/ml) was detected in 45% of patients, 15 days after the second dose, whereas at 3 months, this decreased to 9% (P<0.05) and then increased to 86% after the third dose (P<0.001). Conclusion: In patients with nephropathy and renal replacement therapy, it is necessary to administer a third-dose vaccination within 3 months after the second dose. It is important to continue monitoring the humoral response to obtain a better SARS-CoV-2 vaccination schedule. Competing Interests: Declaration of Competing Interest The authors have no competing interests to declare. (Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu